Elucidating the Molecular Signatures Associated with Elevated Bone Formation Rate by Jestes, Kelli et al.
MUShare
Scholarship, History, Art, Research, and Engagement
MU-COM Research Day College of Osteopathic Medicine
11-9-2018
Elucidating the Molecular Signatures Associated
with Elevated Bone Formation Rate
Kelli Jestes
Marian University - Indianapolis
Krista Jackson OMS-1
Marian University - Indianapolis
Jonathan W. Lowery Ph.D
Marian University - Indianapolis
Follow this and additional works at: https://mushare.marian.edu/mucom_rd
Part of the Medicine and Health Sciences Commons
This Poster is brought to you for free and open access by the College of Osteopathic Medicine at MUShare. It has been accepted for inclusion in MU-
COM Research Day by an authorized administrator of MUShare. For more information, please contact emandity@marian.edu.
Recommended Citation
Jestes, Kelli; Jackson, Krista OMS-1; and Lowery, Jonathan W. Ph.D, "Elucidating the Molecular Signatures Associated with Elevated
Bone Formation Rate" (2018). MU-COM Research Day. 86.
https://mushare.marian.edu/mucom_rd/86
Elucidating the molecular signatures associated with 
elevated bone formation rate
Kelli Jestes, Krista Jackson, Jonathan W. Lowery
Division of Biomedical Science, Marian University College of Osteopathic Medicine, Indianapolis, Indiana
A B
Figure 1: (A) Bmpr2 mutant mice were generated by crossing Bmpr2fl/fl; Prx1-Cre+ males with Bmpr2fl/fl females. Volumetric bone
mineral density (vBMD) was quantified by micro-CT in females at 15 and 55 weeks of age. Mean decline in mg hydroxyapatite per
cubic centimeter for each genotype between 15 and 55 week old cohorts is indicated (mg HA/ccm); gray bars denote 95%
confidence intervals. (B) Quantification of the bone formation marker PINP in sera of control and Bmpr2 mutant mice using
ELISA. Individual samples are represented by circles and group mean by horizontal lines ± SEM; p values determined by
unpaired t test.
Osteoporosis is a disease of decreased bone density that occurs when bone resorption exceeds bone formation,
thereby placing individuals at greater risk of fracture and disability. We previously reported that deletion of the
Bmpr2 gene in embryonic skeletal progenitor cells causes substantially elevated bone density in young
adulthood and reduced age-related decline in bone density, likely due to elevated bone formation rate. Thus,
these mice may serve as a novel model in which to explore the mechanisms regulating bone formation in the
aging skeleton. Here, we performed transcriptome profiling and identified a concise gene signature associated
with elevated bone formation rate in Bmpr2 mutant mice, with 120 transcripts up-regulated and 131 transcripts
down-regulated. Candidate-driven qRT-PCR provided secondary confirmation of this dataset. Notably, only 8 of
these differentially-expressed transcripts have been previously implicated in bone physiology (Pak4, Rpl38,
B2m, Fgf1, Nmu, Phospho1, Smpd3 and Inhbe), thus representing potentially novel regulators of osteoblast
function in the aging skeleton. Additionally, we sought to examine the cell communication events that are
associated with elevated bone formation rate. Using protein samples from control and mutant mice, we took
advantage of recent advancements in high-throughput phospho-profiling antibody arrays, which allow
simultaneous detection of >1,300 targets using very small quantities of protein. These results indicate that the
phosphorylation status of at least 86 signaling effectors is differentially regulated in Bmpr2 mutant mice as
compared to control littermates, including numerous proteins known to regulate osteoblast differentiation
and/or activity. Collectively, our work highlights novel factors associated with elevated bone formation rate and
may identify new opportunities for treating low bone density in humans.
Figure 4: Antibody Array data indicates that phosphorylation of these proteins are increased in Bmpr2-cKO 
mice at 35 weeks of age and are relatively normal at 55 weeks of age.
Figure 5: (A) Results of RNA-Seq analyses at 35 and 55 weeks of age; expressed relative to control. 
(B) Comparison of Bmpr2 mutant results relative to control at 35 and 55 weeks of age represented 
in tabular forms.
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1. Femora obtained from n ≥ 4 each control and 
Bmpr2 mutant mice at 35 weeks and 55 
weeks of age
2. Marrow removed by gentle centrifugation
3. Bones homogenized, total protein collected, 
and concentration determined using BCA 
Assay
4. Each genotype pooled at equal protein 
amounts per mouse
5. Pooled samples were applied to Phospho 
Explorer Antibody Array slides 
6. Protocol was carried out according to the 
manufacturer’s directions with one 
modification of incubating at 4⁰C in the 
protein labeling and coupling steps
7. Signal intensity was determined by Full Moon 
Biosystems on a GenePix4000B scanner 
Imager using GenePix Pro software and 
normalized against beta-actin, GAPDH or 
total protein isoform Figure 2: (A) Schematic of antibody array workflow  provided by Full Moon Biosystems  (B) Slides from our 55 week mutant and control samples, 
detection by Cy3-streptavidin. 
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35 Weeks Old 55 Week Old
Antibody List
Fold Change Fold Change
Slide 2/Slide 1 Slide 2/Slide 1
M-CSF Receptor (Phospho-Tyr561) M-CSF Receptor (Ab-561) 0.46 1.49
Pyk2 (Phospho-Tyr881) Pyk2 (Ab-881) 0.48 0.84
PKC zeta (Phospho-Thr410) PKC zeta (Ab-410)  0.52 0.82
Cyclin B1 (Phospho-Ser147) Cyclin B1 (Ab-147) 0.55 1.29
Tau (Phospho-Ser356) Tau (Ab-356) 0.59 1.16
EGFR (Phospho-Tyr1069) EGFR (Ab-1069) 0.59 1.00
ATP1A1/Na+K+ ATPase1 (Phospho-Ser23) ATP1A1/Na+K+ ATPase1 (Ab-23) 0.60 1.12
CDK1/CDC2 (Phospho-Tyr15) CDK1/CDC2 (Ab-15) 0.60 1.24
PAK1/2 (Phospho-Ser199) PAK1/2 (Ab-199) 0.62 1.47
Ezrin (Phospho-Thr566) Ezrin (Ab-566) 0.63 1.61
CDC25A (Phospho-Ser75) CDC25A (Ab-75) 0.63 1.79
Myosin regulatory light chain 2 (Phospho-Ser18) Myosin regulatory light chain 2 (Ab-18) 0.63 1.43
IRS-1 (Phospho-Ser636) IRS-1 (Ab-636) 0.64 0.95
DAB1 (Phospho-Tyr220) DAB1 (Ab-220) 0.64 0.92
ASK1 (Phospho-Ser966) ASK1 (Ab-966) 0.65 0.80
FGFR1 (Phospho-Tyr766) FGFR1 (Ab-766) 0.65 1.12
EGFR (Phospho-Tyr1197) EGFR (Ab-1197) 0.66 0.80
Src (Phospho-Ser75) Src (Ab-75) 0.66 1.41
CaMK4 (Phospho-Thr196/200) CaMK4 (Ab-196/200) 0.67 0.91
Keratin 8 (Phospho-Ser431) Keratin 8 (Ab-431) 0.67 1.10
Integrin beta-3 (Phospho-Tyr785) Integrin beta-3 (Ab-785) 0.68 1.34
LCK (Phospho-Tyr504) LCK (Ab-504) 0.68 1.32
Chk1 (Phospho-Ser345) Chk1 (Ab-345) 0.68 1.23
Smad3 (Phospho-Ser213) Smad3 (Ab-213) 0.68 1.49
B-RAF (Phospho-Ser446) B-RAF (Ab-446) 0.69 1.00
Caspase 3 (Phospho-Ser150) Caspase 3 (Ab-150) 0.69 0.81
PLD1 (Phospho-Ser561) PLD1 (Ab-561) 0.69 1.28
Ezrin (Phospho-Tyr353) Ezrin (Ab-353) 0.69 1.13
HDAC2 (Phospho-Ser394) HDAC2 (Ab-394) 0.70 0.84
BLNK (Phospho-Tyr96) BLNK (Ab-96) 0.71 1.23
PPAR-gamma (Phospho-Ser112) PPAR-gamma (Ab-112) 0.71 1.24
Met (Phospho-Tyr1003) Met (Ab-1003) 0.72 1.03
HER2 (Phospho-Tyr1221/Tyr1222) HER2 (Ab-1221/1222) 0.72 0.97
TOP2A/DNA topoisomerase II (Phospho-Ser1106) TOP2A/DNA topoisomerase II (Ab-1106) 0.72 0.81
ATF2 (Phospho-Thr69/51) ATF2 (Ab-69/51) 0.73 1.09
ICAM-1 (Phospho-Tyr512) ICAM-1 (Ab-512) 0.73 1.11
Connexin 43 (Phospho-Ser367) Connexin 43 (Ab-367) 0.73 0.90
p53 (Phospho-Ser378) p53 (Ab-378) 0.73 1.07
CaMK2-beta/gamma/delta (Phospho-Thr287) CaMK2-beta/gamma/delta (Ab-287) 0.73 0.98
SYK (Phospho-Tyr525) SYK (Ab-525) 0.74 0.88
EGFR (Phospho-Tyr1016) EGFR (Ab-1016) 0.74 0.95
35 Week Old 55 Week Old
Antibody List
Fold Change Fold Change
Slide 2/Slide 1 Slide 2/Slide 1
HDAC1 (Phospho-Ser421) HDAC1 (Ab-421) 6.89 0.86
Abl1 (Phospho-Tyr204) Abl1 (Ab-204) 3.54 1.20
Chk2 (Phospho-Thr383) Chk2 (Ab-383) 3.22 0.81
E2F1 (Phospho-Thr433) E2F1 (Ab-433) 2.34 0.96
NFAT4 (Phospho-Ser165) NFAT4 (Ab-165) 2.08 1.39
p130Cas (Phospho-Tyr410) p130Cas (Ab-410) 2.06 0.78
HDAC3 (Phospho-Ser424) HDAC3 (Ab-424) 2.03 0.95
FAK (Phospho-Tyr397) FAK (Ab-397) 2.00 1.18
FKHR/FOXO1A (Phospho-Ser329) FKHR/FOXO1A (Ab-329) 1.97 0.74
Src (Phospho-Tyr418) Src (Ab-418) 1.97 1.15
IRS-1 (Phospho-Ser323) IRS-1 (Ab-323) 1.89 0.86
ACC1 (Phospho-Ser79) ACC1 (Ab-79) 1.88 1.02
PAK1/2/3 (Phospho-Thr423/402/421) PAK1/2/3 (Ab-423/402/421) 1.82 0.82
Myc (Phospho-Thr58) Myc (Ab-58) 1.77 0.97
Caspase 9 (Phospho-Tyr153) Caspase 9 (Ab-153) 1.76 0.77
CDK7 (Phospho-Thr170) CDK7 (Ab-170) 1.74 0.89
BAD (Phospho-Ser91/128) BAD (Ab-91/128) 1.72 0.65
14-3-3 beta/zeta (Phospho-Ser184/186) 14-3-3 beta/zeta (Ab-184/186) 1.72 1.22
LAT (Phospho-Tyr191) LAT (Ab-191) 1.71 1.05
STAT6 (Phospho-Thr645) STAT6 (Ab-645) 1.71 0.97
Caspase 9 (Phospho-Ser144) Caspase 9 (Ab-144) 1.69 0.82
LCK (Phospho-Tyr192) LCK (Ab-192) 1.67 1.25
S6 Ribosomal Protein (Phospho-Ser235) S6 Ribosomal Protein (Ab-235) 1.67 0.77
BRCA1 (Phospho-Ser1457) BRCA1 (Ab-1457) 1.65 1.47
Tuberin/TSC2 (Phospho-Ser939) Tuberin/TSC2 (Ab-939) 1.65 1.16
DDX5/DEAD-box protein 5 (Phospho-Tyr593) DDX5/DEAD-box protein 5 (Ab-593) 1.63 1.19
VEGFR2 (Phospho-Tyr951) VEGFR2 (Ab-951) 1.63 1.39
IKK-gamma (Phospho-Ser31) IKK-gamma (Ab-31) 1.63 0.82
P70S6K (Phospho-Thr229) P70S6K (Ab-229) 1.61 0.97
Tau (Phospho-Ser214) Tau (Ab-214) 1.60 0.96
PPAR-BP (Phospho-Thr1457) PPAR-BP (Ab-1457) 1.60 1.22
PLK1 (Phospho-Thr210) PLK1 (Ab-210) 1.59 0.97
Ezrin (Phospho-Tyr478) Ezrin (Ab-478) 1.57 1.17
Rel (Phospho-Ser503) Rel (Ab-503) 1.57 0.75
IGF2R (Phospho-Ser2409) IGF2R (Ab-2409) 1.57 1.43
HSP90 co-chaperone Cdc37 (Phospho-Ser13) HSP90 co-chaperone Cdc37 (Ab-13) 1.55 1.14
MEK1 (Phospho-Thr286) MEK1 (Ab-286) 1.54 0.94
Tuberin/TSC2 (Phospho-Thr1462) Tuberin/TSC2 (Ab-1462) 1.53 1.06
STAM2 (Phospho-Tyr192) STAM2 (Ab-192) 1.53 1.23
Progesterone Receptor (Phospho-Ser190) Progesterone Receptor (Ab-190) 1.53 0.99
ACC1 (Phospho-Ser80) ACC1 (Ab-80) 1.53 0.98
VEGFR2 (Phospho-Tyr1214) VEGFR2 (Ab-1214) 1.52 1.17
FGFR1 (Phospho-Tyr154) FGFR1 (Ab-154) 1.52 0.88
c-PLA2 (Phospho-Ser505) c-PLA2 (Ab-505) 1.51 0.87
VAV2 (Phospho-Tyr142) VAV2 (Ab-142) 1.50 0.84
IL-10R-alpha (Phospho-Tyr496) IL-10R-alpha (Ab-496) 1.50 1.47
AKT1 (Phospho-Ser124) AKT1 (Ab-124) 1.50 0.97
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Possible Repressors of Osteoblast Activity
Figure 3: Antibody Array data indicates that phosphorylation of these proteins are reduced in Bmpr2-cKO 
mice at 35 weeks of age and are relatively normal at 55 weeks of age.   
Possible Drivers of Osteoblast Activity
B
Figure 6: (A) qRT-PCR validates Pak4, Rpl38, Ndfip1 are up in Bmpr2-cKO mice at 35 weeks of age and 
Bglap (osteocalcin) is relatively normal. (B) qRT-PCR validates that Pak4, Rpl38, Ndfip1 and Bglap are all 
relatively normal in Bmpr2-cKO mice at 55 weeks of age. 
Conclusions, Significance & Future Directions:
Abstract
Bmpr2-cKO Model
Antibody Signaling Array Workflow
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Conclusion, Significance & Future Directions:
RNA-Sequencing Data
- Bmpr2 mutant mice display high bone mass in young adulthood and reduced age-related bone loss.
- High throughput antibody signaling arrays of Bmpr2 mutant bones identified 86 possible proteins that can act
as either a repressor or driver of gene expression.
- Genome-wide transcriptome profiling of Bmpr2 mutant bones identified 179 differentially expressed genes
associated with increased osteoblast activity.
- Several genes corresponding with osteoblast differentiation and activity are up-regulated in Bmpr2 mutant
mice.
- Collectively, our findings provide insight into the mechanisms regulating age-related bone loss and highlight
potential targets for therapeutic modulation of bone mass.
- Future studies will involve functional studies to narrow the gene signature to those that regulate osteoblast
function.
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